AC Immune SA (ACIU)

Nasdaq: ACIU · Pharmaceutical Preparations · 1015 Lausanne, CH · filing with the SEC since 2015

Full chart Alerts Compare

Grade4.4

◀ Past 5.3● Present 4.1▶ Future 3.9

2 est.

Overview Business Financials Grade Forecast Sentiment Ownership People Filings Patents Chart

The companyfiscal 2025, as filed

RevenueCHF 3.6M-86.9%

Net income-CHF 70.4M-38.4%

Earnings per shareCHF -0.70-37.3%

Operating cash flow-CHF 69.3M-205.2%

CashCHF 26.8M-26.1%

Debtn/a

Shareholders’ equityCHF 44.9M-60.0%

Shares, diluted100.8M+1.1%

Return on equity-156.9%

The recordfrom its filings

Filings in 202640

Newest filingNov 4 · 6-K

Annual reportMar 13, 2026

Quarterly reportn/a

Next report due20-F by Apr 30

Insider sales, 12 months$100,000

Insider buys, 12 months$0.00

Patents granted64

Filer categoryAccelerated filer

Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.

Revenue and net income by fiscal yearRevenueNet income

16171819202122232425

As filed, in CHF. Nothing here is a forecast.

News

Nov 4, 2026 · SEC EDGAR · Form 6-K

Interim report, foreign filer

Open the filing on sec.gov

Oct 9, 2026 · SEC EDGAR · Form 3

Insider holding, initial

Open the filing on sec.gov

Oct 9, 2026 · SEC EDGAR · Form 3/A

Insider holding, amended

Open the filing on sec.gov

Oct 2, 2026 · SEC EDGAR · Form 6-K

Interim report, foreign filer

Open the filing on sec.gov

Sep 23, 2026 · SEC EDGAR · Form 6-K

Interim report, foreign filer

Open the filing on sec.gov

Sep 3, 2026 · SEC EDGAR · Form 6-K

Interim report, foreign filer

Open the filing on sec.gov

Aug 20, 2026 · SEC EDGAR · Form 6-K

Interim report, foreign filer

Open the filing on sec.gov

Aug 11, 2026 · SEC EDGAR · Form 6-K

Interim report, foreign filer

Open the filing on sec.gov

Aug 5, 2026 · SEC EDGAR · Form 6-K

Interim report, foreign filer

Open the filing on sec.gov

Jun 30, 2026 · SEC EDGAR · Form 6-K

Interim report, foreign filer

Open the filing on sec.gov

An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.

SI brieffrom the record

Core business

AC Immune SA is classed by the SEC under Pharmaceutical Preparations (industry code 2834), based in 1015 Lausanne, CH.

Newest on the record

Interim report, foreign filer on Nov 4. Before it, insider holding, initial on Oct 9.

What is due next

The 20-F for the period to Dec 31, 2026, due by Apr 30, 2027.

About ACIU

AC Immune SA is classed by the SEC under Pharmaceutical Preparations (industry code 2834), based in 1015 Lausanne, CH. In its latest annual figures on file, for the fiscal year ended 2025-12-31, it reported revenue of CHF 3.6 million and a loss of CHF 70 million (its filed statements).

IndustryPharmaceutical Preparations

Headquarters1015 Lausanne, CH

Business modelPre-revenue company

ExchangeNasdaq

Filing since2015

Fiscal year endsDec 31

SEC number (CIK)1651625

Peers on fileLLY, KROS, CORT, UTHR

Who runs it

Financial performance

In fiscal 2025 AC Immune SA’s revenue was CHF 3.57 million, down 86.9% from CHF 27.31 million the year before. It made a net loss of CHF 70.45 million.

Annual report, filed Mar 13, 2026.

Financial statements

The grade

AC Immune SA grades 4.4 of 10 against its own industry, the 497 companies in Pharmaceutical Preparations. Seven of the nine metrics are read as filed and two are SI estimates, each with its reasoning.

◀ Past5.3

● Present4.1

▶ Future3.9

How the grade is made

Forecast

Every forecast is registered before the outcome, with the rule that settles it. A miss stays on the page.

Company forecasts

SI Assistanton ACIU · research, not advice